Status:
RECRUITING
Duobrii in Combination With Biologics
Lead Sponsor:
Psoriasis Treatment Center of Central New Jersey
Collaborating Sponsors:
Ortho Dermatologics
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Detailed Description
A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks
Eligibility Criteria
Inclusion
- Male or female adult ≥ 18 years of age;
- Diagnosis of chronic plaque-type
- Psoriasis affecting 2%-10% BSA
- Patient is being treated with biologic therapy for a minimum of 24 weeks
- Able and willing to give written informed consent prior to performance of any study-related procedures
Exclusion
- Psoriasis affecting ˂2% or \>10% BSA
- Patient not receiving a biologic agent, or receiving biologic agent \<24weeks
- Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
- Has previously used DUOBRII
Key Trial Info
Start Date :
October 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04119102
Start Date
October 14 2019
End Date
September 1 2020
Last Update
April 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States, 08520